Psilocybin therapy: what do we know? | Dr James Rucker | The Royal Institution

Psilocybin therapy represents a paradigm shift in mental health treatment, moving away from daily symptom management toward discrete, intensive experiences that facilitate cognitive flexibility and emotional processing. Historical medical usage and the subsequent prohibition era have given way to modern clinical trials investigating its efficacy for treatment-resistant depression and other affective disorders. Brain network connectivity undergoes a significant transformation during the psilocybin experience, characterized by a temporary breakdown of the default mode network and an increase in global communication between disparate brain regions. This plasticity allows patients to break out of rigid, negative thought patterns, potentially resetting neural loops that contribute to chronic depressive states. Clinical safety protocols prioritize the psychological setting and professional supervision to mitigate risks and maximize therapeutic outcomes. Evidence suggests that while the subjective experience is profound, the long-term benefits are largely dependent on the integration process that follows the psychedelic session.